Back to Journals » OncoTargets and Therapy » Volume 11

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder

Authors Yu Z, Quiroz E, Shen Y, Jaiyesimi IA

Received 13 June 2018

Accepted for publication 16 August 2018

Published 4 December 2018 Volume 2018:11 Pages 8723—8728

DOI https://doi.org/10.2147/OTT.S177111

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Takuya Aoki


Zhou Yu,1 Elisa Quiroz,2 Yulei Shen,3 Ishmael A Jaiyesimi1

1Department of Hematology and Oncology, William Beaumont Hospital, Oakland University – William Beaumont School of Medicine, Royal Oak, MI, USA; 2Department of Internal Medicine, William Beaumont Hospital, Oakland University – William Beaumont School of Medicine, Royal Oak, MI, USA; 3Department of Pathology and Laboratory Medicine, William Beaumont Hospital, Oakland University – William Beaumont School of Medicine, Royal Oak, MI, USA

Abstract: Historically, patients with locally advanced or metastatic melanoma have an extremely poor prognosis. In recent years, major breakthroughs in cutaneous melanoma treatment have led to remarkable improvements in patient outcomes. However, there are limited published data on the efficacy of these novel therapies in the treatment of mucosal melanoma due to rarity of the disease. We report a case of successful neoadjuvant targeted therapy with BRAF and MEK inhibitors followed by radical surgical excision in a patient with advanced malignant melanoma of the gallbladder.

Keywords: melanoma, gallbladder, BRAF V600E mutation, neoadjuvant, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]